Takeda Pharmaceutical Co Ltd (NYSE:TAK)
$ 13.45 -0.11 (-0.81%) Market Cap: 42.99 Bil Enterprise Value: 70.33 Bil PE Ratio: 22.63 PB Ratio: 0.94 GF Score: 79/100

Q1 2023 Takeda Pharmaceutical Co Ltd Earnings Call Transcript

Jul 28, 2022 / 10:00AM GMT
Release Date Price: $14.81 (+0.82%)
Ayako Iwamuro
Takeda Pharmaceutical Company Limited - Manager of IR and Global Finance

[Interpreted] Good evening, everybody, or good morning, everybody. Thank you very much for joining Takeda's earnings conference call webinar for the first quarter FY 2022. I will serve as MC today. My name is Ayako Iwamuro, in charge of Global IR.

First, I will explain language setup. (Operator Instructions)

Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today.

The factors that could cause our actual results to differ materially are discussed in our most recent Form 20-F and in other SEC filings of Takeda. Please also refer to the important notice on Page 2 of the presentation.

Let's move to the presentation today. We have with us Christophe Weber, President and CEO; R&D President, Andy Plump; and Chief Financial Officer, Constantine Saroukos. They will be presenting. After the presentation, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot